Onyx Pharmaceuticals, Inc. Message Board
- Reply to
Analysts Ranking April & May - All in $140's to $150's . READ
by unforgetablgirl •May 27, 2013 1:24 PMgreat DD work. Thanks Looks Great : ))))))))))))))
- Reply to
This Stock Seems To Bounce From $122's to $126's Fast & Furious Every Time.
by mynameissteve258 •May 25, 2013 11:32 AMshortttt squeezeeeeee coming Tuesday.
-
stay with the winners.
-
Motley Fool
3 Stocks Near 52-Week Highs Worth Selling
By Sean Williams | More Articles | Save For Later
May 24, 2013 | - Reply to
CNN MONEY :. ADVERTISERS WILL NOT USE TIMBLR BECAUSE OF IT'S CONTENT. LINK
by tommyhill685 •May 20, 2013 2:01 PMgot 2 downgrades this evening
-
- Reply to
Did DD Analysts Targets $34 to $40 on Facebook. *** post.
by going1green •May 20, 2013 3:52 PMridiculously cheap
-
see you at $28+
- Reply to
FB is Like a Rubber Ball - Always Bounces Right Back.
by sharkman683 •May 20, 2013 11:30 AMalso bought today
- Reply to
FB Beat Estimate/ Made 1.46 BILLION in Reveune w/ 30% Mobile Growth- UNDERvalued. LINKED
by raytrader362 •May 20, 2013 12:36 PMbought today..cheap
- Reply to
High LDL Leads to Heart Attacks * Lovaza RAISES LDL 45% * Vascepa Lowers LDL
by tradinghulkman •May 17, 2013 5:20 PMthanks
- Reply to
Scripts Continue To Rise-- 3,224 to 7,260 to 11,768 and Just Announced 15,005 NICE !
by ccharles792 •May 19, 2013 9:19 PMthanks just saw chart looks great !
- Reply to
Article : AMRN SALES GROWING,AVERAGE PT is $17.65/ VERY UNDERVALUED (link )
by terridiamond158 •May 19, 2013 11:33 AMcouldn't have said it better
-
AMRN scripts Grew from 11,768 to 14,976 In Just A Week. The 3035 is the number of more scripts written in that one week but total scripts in that week were 14976
-
Research Report ST Amarin Week Ending Growth Rate EXCEEDING 100 M- 2013.
-
May 17, 2013 By' Pearson-Lardman Article Where Is Amarin Really?
Not to mention the Big Name and More Reputable Institutions like Jefferies, JP Morgan, Leerink Swan, Canaccord and Citi have Price Targets from $13-$39, with an average PT of $17.65 however, these go overlooked and pushed to the side.
In conclusion you can make all the speculation you want around NCE, but with the Patent Portfolio that AMRN has built up and the FACT that Vascepa will be the 1st ever drug to enter the ANCHOR Market, NCE clearly does not justify why AMRN should be trading at the $7-$8 range. In my opinion AMRN is very undervalued at this level and hopefully the continued week to week and month to month script growth aswell as the upcoming Combo-Statin Data will help get AMRN stock to a level of true valuation before the drug Launches in the ANCHOR Market and/or Partners up with a Big Pharma. - Reply to
High LDL Leads to Heart Attacks * Lovaza RAISES LDL 45% * Vascepa Lowers LDL
by tradinghulkman •May 17, 2013 5:20 PMno brainer.
- Reply to
With NCE Out of The Way, Will Go Back to $8 On Increased Sales
by terridiamond158 •May 17, 2013 4:19 PMis this posting?